Feb. 27 at 3:19 PM
$INTS they've already done the "heavy lifting" part of developing an effective drug that increased the lives of cancer patients for several types of cancer. The next trials only have dosing changes and process changes so I would once again expect solid results. This stock is still WAY undervalued and I expect it will be above
$10 in the next couple months if not sooner. It should also get a decent bump when it regains NASDAQ compliance and could explode to
$60!with more solid results.
